Zhang Guojun, Zhang Zhe, Liu Zhuogang
Department of Hematology, Shengjing Hospital of China Medical University, Shenyang City, 110022, People's Republic of China.
Tumour Biol. 2013 Jun;34(3):1887-94. doi: 10.1007/s13277-013-0732-0. Epub 2013 Mar 14.
Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target for highly specific cancer therapy for several reasons. However, the functional significance of Plk1 in renal cell carcinoma (RCC) has not been reported. To explore whether Plk1 plays a general role in renal carcinoma, we examined the expression of Plk1 protein in renal urothelial carcinoma and cell lines, and analyzed the relationship between Plk1 protein expression and development, proliferation, and invasion of renal carcinoma. Immunohistochemisty was used to detect the expression of Plk1 in 100 renal carcinoma tissues. Moreover, the expression of Plk1 was analyzed by western blot and real-time polymerase chain reaction (PCR) in 80 renal carcinoma tissues and 20 normal renal tissues. CCK-8 assay, colony formation assay, and Transwell assay were used to examine proliferation and invasion ability of renal cancer cells with treatment of scytonemin (the specific inhibitor of Plk1). Statistical analysis was used to discuss the association between Plk1 expression and clinicopathologic parameters, and proliferation and invasion ability of renal cancer cells. Plk1 expressions were greater in cancerous tissues than in normal tissues (P<0.05). With an increase in tumor grade and stage, tumor metastasis, and recurrence, the level of Plk1 increased significantly in renal cancerous tissues. Moreover, there was a significantly higher expression of Plk1 in higher degree of malignant renal adenocarcinoma cell ACHN than that in renal adenocarcinoma cell 769-P. With increasing concentration of scytonemin, we found that cell proliferation and invasion activity decreased significantly. Plk1 expression status was closely correlated with important histopathologic characteristics (grades, stages, metastasis, and recurrence) of renal carcinomas. Furthermore, Plk1 played an important function on renal cancer cells' proliferation and invasion.
由于多种原因，Polo样激酶1（Plk1）作为一种生物标志物以及高度特异性癌症治疗的靶点，是一个引人关注的分子。然而，Plk1在肾细胞癌（RCC）中的功能意义尚未见报道。为了探究Plk1在肾癌中是否发挥普遍作用，我们检测了Plk1蛋白在肾尿路上皮癌组织及细胞系中的表达，并分析了Plk1蛋白表达与肾癌发生、增殖及侵袭之间的关系。采用免疫组织化学法检测100例肾癌组织中Plk1的表达。此外，运用蛋白质免疫印迹法和实时聚合酶链反应（PCR）分析80例肾癌组织及20例正常肾组织中Plk1的表达。采用CCK - 8法、集落形成试验和Transwell试验检测经scytonemin（Plk1的特异性抑制剂）处理的肾癌细胞的增殖和侵袭能力。运用统计学分析探讨Plk1表达与临床病理参数以及肾癌细胞增殖和侵袭能力之间的关联。Plk1在癌组织中的表达高于正常组织（P<0.05）。随着肿瘤分级、分期、转移及复发的增加，肾癌组织中Plk1水平显著升高。此外，恶性程度较高的肾腺癌ACHN细胞中Plk1的表达明显高于肾腺癌细胞769 - P。随着scytonemin浓度的增加，我们发现细胞增殖和侵袭活性显著降低。Plk1表达状态与肾癌的重要组织病理学特征（分级、分期、转移和复发）密切相关。此外，Plk1在肾癌细胞的增殖和侵袭中发挥重要作用。
